XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition and Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 88,694 $ 65,755 $ 246,318 $ 185,045
Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 88,694 65,755 236,318 185,045
Revenue from collaborative arrangements with a related party        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 0 0 10,000 0
GSK        
Revenue Recognition and Collaborative Arrangements        
Total net revenue 88,694 65,755 246,318 185,045
GSK | Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 92,150 69,211 246,686 195,413
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)
Total net revenue 88,694 65,755 236,318 185,045
GSK | RELVAR/BREO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 63,893 46,433 165,612 136,259
GSK | ANORO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 11,882 11,548 32,931 30,753
GSK | TRELEGY        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 16,375 11,230 48,143 28,401
GSK | Revenue from collaborative arrangements with a related party | Strategic alliance - MABA program        
Revenue Recognition and Collaborative Arrangements        
Total net revenue $ 0 $ 0 $ 10,000 $ 0